Radiolabelled GLP-1 receptor antagonist binds to GLP-1 receptor-expressing human tissues

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 6, 2014, Pages 1166-1171

  Waser, Beatrice ^a   Reubi, Jean Claude ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Exendin(9 39) antagonist; GLP 1 receptors; Human tumours; Peptide receptors; Tumour targeting

Indexed keywords

BOLTON HUNTER EXENDIN(9-39) ANTAGONIST I 125; GLUCAGON LIKE PEPTIDE 1 (7-36)AMIDE AGONIST I 125; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCAGON LIKE PEPTIDE 1 RECEPTOR ANTAGONIST; HORMONE RECEPTOR BLOCKING AGENT; LYSINE; RADIOLIGAND; UNCLASSIFIED DRUG; 125I-BOLTON-HUNTER-EXENDIN(9-39); BOLTON-HUNTER REAGENT; EXENDIN (9-39); GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; PEPTIDE FRAGMENT; PROTEIN BINDING; RADIOPHARMACEUTICAL AGENT; SUCCINIMIDE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IC 50; IN VITRO STUDY; INSULINOMA; ISOTOPE LABELING; MENINGIOMA; MOLECULAR IMAGING; NONHUMAN; PARAGANGLIOMA; PHEOCHROMOCYTOMA; RAT; THYROID MEDULLARY CARCINOMA; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DIAGNOSTIC USE; METABOLISM; NEOPLASM; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; HUMANS; NEOPLASMS; PEPTIDE FRAGMENTS; PROTEIN BINDING; RADIOPHARMACEUTICALS; RATS; RECEPTORS, GLUCAGON; SUCCINIMIDES; TISSUE DISTRIBUTION;

EID: 84900833578     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2684-4     Document Type: Article

References (23)

1. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-39.
2. Körner M, Stöckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007;48:736-43.
3. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30:781-93.
4. Holst JJ, Vilsbøll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009;297:127-36.
5. Drucker DJ, Dritselis A, Kirkpatrick P. Liraglutide. Nat Rev Drug Discov 2010;9:267-8.
6. Wild D, Christ E, Caplin M, Kurzawinski TR, Forrer F, Brändle M, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med 2011;52:1073-8.
7. Christ E, Wild D, Reubi JC. Glucagonlike peptide-1 receptor: an example of translational research in insulinomas: a review. Endocrinol Metab Clin North Am 2010;39:791-800.
8. Christ E, Wild D, Forrer F, Brändle M, Sahli R, Clerici T, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab 2009;94:4398-405.
9. Wild D, Mäcke H, Christ E, Gloor B, Reubi JC. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med 2008;359:766-8.
10. Sowa-Staszczak A, Pach D, Mikołajczak R, Mäcke H, Jabrocka-Hybel A, Stefańska A, et al. Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma. Eur J Nucl Med Mol Imaging 2013;40:524-31.
11. Christ E, Wild D, Ederer S, Béhé M, Nicolas G, Caplin ME, et al. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. Lancet Diabetes Endocrinol 2013;1:115-22.
12. Brom M, Joosten L, Oyen WJ, Gotthardt M, Boerman OC. Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas. Contrast Media Mol Imaging 2012;7:160-6.
13. Waser B, Tamma ML, Cescato R, Maecke HR, Reubi JC. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med 2009;50:936-41.
14. Wild D, Fani M, Behe M, Brink I, Rivier J, Reubi JC, et al. First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med 2011;52:1412-7.
15. Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, Piccand V, et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 2008;49:318-26.
16. Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A 2006;103:16436-41.
17. Thorens B, Porret A, Bühler L, Deng SP, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993;42:1678-82.
18. Mukai E, Toyoda K, Kimura H, Kawashima H, Fujimoto H, Ueda M, et al. GLP-1 receptor antagonist as a potential probe for pancreatic beta-cell imaging. Biochem Biophys Res Commun 2009;389:523-6.
19. Waser B, Reubi JC. Value of the radiolabelled GLP-1 receptor antagonist exendin(9-39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humans. Eur J Nucl Med Mol Imaging 2011;38:1054-8.
20. Kähkönen E, Jambor I, Kemppainen J, Lehtiö K, Grönroos TJ, Kuisma A, et al. In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. Clin Cancer Res 2013;19:5434-43.
21. Connolly BM, Vanko A, McQuade P, Guenther I, Meng X, Rubins D, et al. Ex vivo imaging of pancreatic beta cells using a radiolabeled GLP-1 receptor agonist. Mol Imaging Biol 2012;14:79-87.
22. Cescato R, Waser B, Fani M, Reubi JC. Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. J Nucl Med 2011;52:1886-90.
23. Bodei L, Paganelli G, Mariani G. Receptor radionuclide therapy of tumors: a road from basic research to clinical applications. J Nucl Med 2006;47:375-7.